Lipigon Pharmaceuticals AB (LPGO) — Cash Flow-to-Debt Ratio
Lipigon Pharmaceuticals AB (LPGO) has a Cash Flow-to-Debt Ratio of -1.79x as of December 2025, meaning its operating cash flow of Skr-6.38 Million could theoretically repay -2% of its total liabilities (Skr3.57 Million) in one year. See LPGO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lipigon Pharmaceuticals AB Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Lipigon Pharmaceuticals AB across 8 annual periods. Also explore net asset growth rate of Lipigon Pharmaceuticals AB to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Lipigon Pharmaceuticals AB (2018–2025)
Year-by-year debt coverage analysis for Lipigon Pharmaceuticals AB. For market capitalisation and broader financial context, see how much is Lipigon Pharmaceuticals AB worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.01x | Skr-35.77 Million | Skr3.57 Million | ▼ -185.3% |
| 2024 | -3.51x | Skr-24.78 Million | Skr7.06 Million | ▼ -26.4% |
| 2023 | -2.78x | Skr-14.32 Million | Skr5.16 Million | ▲ +48.5% |
| 2022 | -5.39x | Skr-37.47 Million | Skr6.95 Million | ▲ +1.2% |
| 2021 | -5.46x | Skr-35.30 Million | Skr6.47 Million | ▼ -43.0% |
| 2020 | -3.82x | Skr-8.62 Million | Skr2.26 Million | ▲ +28.5% |
| 2019 | -5.34x | Skr-5.56 Million | Skr1.04 Million | ▼ -74.6% |
| 2018 | -3.06x | Skr-3.26 Million | Skr1.07 Million | — |